PRTN3 and rheumatoid arthritis: As abatacept blocks T-cell activation, indirectly influencing interaction between T-cells and antibody producing B-cells, and rituximab depletes populations of active B-cells, it is not surprising that these drugs should be somewhat more effective in patients with RA that are seropositive for ACPA or RF.